Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL

Risinskaya, Natalya; Kozhevnikova, Yana; Gavrilina, Olga A.; Chabaeva, Julia; Kotova, Ekaterina; Yushkova, Anna; Isinova, Galina; Zarubina, Ksenija I.; Obukhova, Tatiana N.; Kulikov, Sergey; Julhakyan, Hunan; Sudarikov, Andrey; Паровичникова, Е Н

doi:10.3390/genes13030398

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This robust research tool provides information on a variety of changes in the genome, including chromosome aberrations and small deletions and insertions of several nucleotides. Previously, we studied the STR profiles of tumor cells in patients with acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma and observed two types of aberrations—loss of heterozygosity (LOH) and elevated microsatellite alteration at selected tetranucleotide repeats (EMAST) [ 13 , 14 , 15 , 16 ]. When verified by the microarray, the STR loci with LOH were always in the region of large deletions or a copy neutral loss of heterozygosity.…”

Section: Introductionmentioning

confidence: 99%

Accumulation of STR-Loci Aberrations in Subclones of Jurkat Cell Line as a Model of Tumor Clonal Evolution

Risinskaya

Глинщикова

Makarik

et al. 2023

Genes

Self Cite

View full text Add to dashboard Cite

Many genetic markers are known to distinguish tumor cells from normal. Genetic lesions found at disease onset often belong to a predominant tumor clone, and further observation makes it possible to assess the fate of this clone during therapy. However, minor clones escape monitoring and become unidentified, leading to relapses. Here we report the results of in vitro study of clonal evolution in cultured tumor cell line (Jurkat) compared to the cell line of non-tumor origin (WIL2-S). Cell lines were cultured and cloned by limiting dilutions. Subclones were tested by short tandem repeats (STR) profiling. Spontaneous STR aberrations in cells of non-tumor origin occur in less than 1 of 100 cultured cells. While in the cells of tumor origin, new aberrations appear in 1 or even more of 3 cultured cells. At the same time, a significant relationship was found between the accumulation of aberrations in the pool of subclones and the rate of cell growth. One can speculate that this approach could be applied for the analysis of primary patient tumor cell culture to obtain information concerning the evolutionary potential of the tumor cells that may be useful for the selection of a therapy approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Accumulation of STR-Loci Aberrations in Subclones of Jurkat Cell Line as a Model of Tumor Clonal Evolution

Risinskaya

Глинщикова

Makarik

et al. 2023

Genes

Self Cite

View full text Add to dashboard Cite

show abstract

“…Figure2. Karyotype of a patient with the loss of heterozygosity and normal karyotype according to the standard cytogenetic analysis[31]. Purple symbols refer to loss of heterozygosity.…”

mentioning

confidence: 99%

Effect of Carcinomas on Autosomal Trait Screening: A Review Article

Alhatim,

Abdullah,

Abu Bakar

et al. 2023

CIMB

View full text Add to dashboard Cite

This review highlights the effect of carcinomas on the results of the examination of autosomal genetic traits for identification and paternity tests when carcinoid tissue is the only source and no other samples are available. In DNA typing or genetic fingerprinting, variable elements are isolated and identified within the base pair sequences that form the DNA. The person’s probable identity can be determined by analysing nucleotide sequences in particular regions of DNA unique to everyone. Genetics plays an increasingly important role in the risk stratification and management of carcinoma patients. The available information from previous studies has indicated that in some incidents, including mass disasters and crimes such as terrorist incidents, biological evidence may not be available at the scene of the accident, except for some unknown human remains found in the form of undefined human tissues. If these tissues have cancerous tumours, it may affect the examination of the genetic traits derived from these samples, thereby resulting in a failure to identify the person. Pathology units, more often, verify the identity of the patients who were diagnosed with cancer in reference to their deceased tumorous relatives. Genetic fingerprinting (GF) is also used in paternity testing when the alleged parent disappeared or died and earlier was diagnosed and treated for cancer.

show abstract

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma

Firsova

Solovev

Nikulina

et al. 2023

Genes

View full text Add to dashboard Cite

Multiple myeloma (MM) is characterized by heterogeneity of tumor cells. The study of tumor cells from blood, bone marrow, plasmacytoma, etc., allows us to identify similarities and differences in tumor lesions of various anatomical localizations. The aim of this study was to compare the loss of heterozygosity (LOH) by tumor cells by assessing STR profiles of different MM lesions. We examined paired samples of plasma circulating tumor DNA (ctDNA) and CD138+ bone marrow cells in MM patients. For patients with plasmacytomas (66% of 38 patients included), the STR profile of plasmacytomas was also studied when biopsy samples were available. Diverse patterns of LOH were found in lesions of different localization for most patients. LOH in plasma ctDNA, bone marrow, and plasmacytoma samples was found for 55%, 71%, and 100% of patients, respectively. One could expect a greater variety of STR profiles in aberrant loci for patients with plasmacytomas. This hypothesis was not confirmed—no difference in the frequency of LOH in MM patients with or without plasmacytomas was found. This indicates the genetic diversity of tumor clones in MM, regardless of the presence of extramedullar lesions. Therefore, we conclude that risk stratification based on molecular tests performed solely on bone marrow samples may not be sufficient for all MM patients, including those without plasmacytomas. Due to genetic heterogeneity of MM tumor cells from various lesions, the high diagnostic value of liquid biopsy approaches becomes obvious.

show abstract

Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL

Cited by 3 publications

References 33 publications

Accumulation of STR-Loci Aberrations in Subclones of Jurkat Cell Line as a Model of Tumor Clonal Evolution

Accumulation of STR-Loci Aberrations in Subclones of Jurkat Cell Line as a Model of Tumor Clonal Evolution

Effect of Carcinomas on Autosomal Trait Screening: A Review Article

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma

Contact Info

Product

Resources

About